POP-OUT | CLOSE
 
 
7-[2-(4-FLUORO-PHENYL)-5-ISOPROPYL-3-PHENYL-4-PHENYLCARBAMOYL-PYRROL-1-YL]- 3,5-DIHYDROXY-HEPTANOIC ACID
 
117 is found in 1 entries
117
  •   Chemical Component Summary   Hide
    Name 7-[2-(4-FLUORO-PHENYL)-5-ISOPROPYL-3-PHENYL-4-PHENYLCARBAMOYL-PYRROL-1-YL]- 3,5-DIHYDROXY-HEPTANOIC ACID
    Identifiers (3R,5R)-7-[2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid
    (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-yl-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid
    Synonyms ATORVASTATIN
    Formula C33 H35 F N2 O5
    Molecular Weight 558.64 g/mol
    Type non-polymer
    Isomeric SMILES
    InChI
    InChI key XUKUURHRXDUEBC-KAYWLYCHSA-N
     
  •   Drug Info: DrugBank Hide
    DrugBank ID DB01076   (Different stereochemistry)
    Name Atorvastatin
    Groups approved
    Description Atorvastatin (Lipitor) is a member of the drug class known as statins. It is used for lowering cholesterol. Atorvastatin is a competitive inhibitor of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-determining enzyme in cholesterol biosynthesis via the mevalonate pathway. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonate. Atorvastatin acts primarily in the liver. Decreased hepatic cholesterol levels increases hepatic uptake of cholesterol and reduces plasma cholesterol levels.
    Synonyms Lipovastatinklonal
    Salts Atorvastatin Calcium
    Brand names
    • Atogal
    • Cardyl
    • Faboxim
    • Hipolixan
    • Lipitor
    • Lipotropic
    • Liprimar
    • Lowden
    • Normalip
    • Sincol
    • Sortis
    • Torvacard
    • Torvast
    • Totalip
    • Tulip
    • Vastina
    • Xanator
    • Xarator
    • Zurinel
    [more]
    Affected organism Humans and other mammals
    Indication May be used as primary prevention in individuals with multiple risk factors for coronary heart disease (CHD) and as secondary prevention in individuals with CHD to reduce the risk of myocardial infarction (MI), stroke, angina, and revascularization procedures. May be used to reduce the risk of cardiovascular events in patients with acute coronary syndrome (ACS). May be used in the treatment of primary hypercholesterolemia and mixed dyslipidemia, homozygous familial hypercholesterolemia, primary dysbetalipoproteinemia, and/or hypertriglyeridemia as an adjunct to dietary therapy to decrease serum total and low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (apoB), and triglyceride concentrations, while increasing high-density lipoprotein cholesterol (HDL-C) levels.
    Pharmacology Atorvastatin, a selective, competitive HMG-CoA reductase inhibitor, is used to lower serum total and LDL cholesterol, apoB, and triglyceride levels while increasing HDL cholesterol. High LDL-C, low HDL-C and high TG concentrations in the plasma are associated with increased risk of atherosclerosis and cardiovascular disease. The total cholesterol to HDL-C ratio is a strong predictor of coronary artery disease and high ratios are associated with higher risk of disease. Increased levels of HDL-C are associated with lower cardiovascular risk. By decreasing LDL-C and TG and increasing HDL-C, atorvastatin reduces the risk of cardiovascular morbidity and mortality. Atorvastatin has a unique structure, long half-life, and hepatic selectivity, explaining its greater LDL-lowering potency compared to other HMG-CoA reductase inhibitors.
    Mechanism of action Atorvastatin selectively and competitively inhibits the hepatic enzyme HMG-CoA reductase. As HMG-CoA reductase is responsible for converting HMG-CoA to mevalonate in the cholesterol biosynthesis pathway, this results in a subsequent decrease in hepatic cholesterol levels. Decreased hepatic cholesterol levels stimulates upregulation of hepatic LDL-C receptors which increases hepatic uptake of LDL-C and reduces serum LDL-C concentrations.
    Route of administration Oral
    Categories
    • Anticholesteremic Agents
    • Hydroxymethylglutaryl-CoA Reductase Inhibitors
    ATC-Code C10AA05
    AHFS-Code 24:06.08
    CAS number 134523-00-5
    Targets
    Name Sequence search Pharmacological action Actions
    3-hydroxy-3-methylglutaryl-coenzyme A reductase   Search  yes inhibitor
    Dipeptidyl peptidase 4   Search  no inhibitor
    Aryl hydrocarbon receptor   Search  unknown agonist
     
Ligand Image